Obesity and adipokines: Effects on sympathetic overactivity

Journal of Physiology

Volumn 590, Issue 8, 2012, Pages 1787-1801

  Smith, Michael M ^a   Minson, Christopher T ^a  

^a UNIVERSITY OF OREGON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSINOGEN; C REACTIVE PROTEIN; FATTY ACID; INSULIN; INTERLEUKIN 6; LEPTIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADRENERGIC SYSTEM; AUTONOMIC NERVOUS SYSTEM FUNCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SIGNALING; METABOLIC SYNDROME X; MUSCLE SYMPATHETIC NERVE ACTIVITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC OVERACTIVITY; SYMPATHETIC TONE;

ADIPOKINES; ANIMALS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84859721989     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2011.221036     Document Type: Review

References (158)

1. Alvarez GE, Ballard TP, Beske SD & Davy KP (2004). Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol Heart Circ Physiol 287, H414-418.
2. Alvarez GE, Beske SD, Ballard TP & Davy KP (2002). Sympathetic neural activation in visceral obesity. Circulation 106, 2533-2536.
3. Alvarez GE, Davy BM, Ballard TP, Beske SD & Davy KP (2005). Weight loss increases cardiovagal baroreflex function in obese young and older men. Am J Physiol Endocrinol Metab 289, E665-669.
4. Anderson EA, Hoffman RP, Balon TW, Sinkey CA & Mark AL (1991). Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87, 2246-2252.
5. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T & Matsuzawa Y (1999). Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79-83.
6. Arnold AC, Shaltout HA, Gallagher PE & Diz DI (2009). Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus. Hypertension 54, 1001-1008.
7. Arone LJ, Mackintosh R, Rosenbaum M, Leibel RL & Hirsch J (1995). Autonomic nervous system activity in weight gain and weight loss. Am J Physiol Regul Integr Comp Physiol 269, R222-225.
8. Banks WA, Kastin AJ & Broadwell RD (1995). Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 2, 241-248.
9. Bastard JP, Jardel C, Delattre J, Hainque B, Bruckert E & Oberlin F (1999). Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 99, 2221-2222.
10. Berne C, Fagius J, Pollare T & Hjemdahl P (1992). The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia 35, 873-879.
11. Beske SD, Alvarez GE, Ballard TP & Davy KP (2002). Reduced cardiovagal baroreflex gain in visceral obesity: implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol 282, H630-635.
12. Brabant G, Horn R, von zur Mühlen A, Mayr B, Wurster U, Heidenreich F, Schnabel D, Grüters-Kieslich A, Zimmermann-Belsing T & Feldt-Rasmussen U (2000). Free and protein bound leptin are distinct and independently controlled factors in energy regulation. Diabetologia 43, 438-442.
13. Bruce R, Godsland I, Walton C, Crook D & Wynn V (1994). Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism 43, 1275-1281.
14. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA & Marmot MG (2002). Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 106, 2659-2665.
15. Campese VM, Shaohua Y & Huiquin Z (2005). Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 46, 533-539.
16. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z & Chiu J (2004). Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 287, H695-703.
17. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, Basdevant A, Bar Hen A, Bedossa P, Guerre-Millo M & Clement K (2006). Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55, 1554-1561.
18. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK & Febbraio MA (2008). Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55 2688-2697.
19. Cassaglia P, Hermes S, Aicher S & Brooks V (2011). Insulin acts in the arcuate nucleus to increase lumbar sympathetic nerve activity and baroreflex function in rats. J Physiol 589, 1643-1662.
20. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M, Skibinski GA, McCrory MA, Szalai AJ & Zhao AZ (2006). Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 12, 425-432.
21. Chrousos GP (1995). The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 332, 1351-1362.
22. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, Giorgino R & De Pergola G (2001). Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 25, 805-810.
23. Ciofi P (2011). The arcuate nucleus as a circumventricular organ in the mouse. Neurosci Lett 487, 187-190.
24. Coppari R, Ichinose M, Lee CE, Pullen AE, Kenny CD, McGovern RA, Tang V, Liu SM, Ludwig T, Chua SC, Lowell BB & Elmquist JK (2005). The hypothalamic arcuate nucleus: a key site for mediating leptin's effects on glucose homeostasis and locomotor activity. Cell Metab 1, 63-72.
25. Cox HS, Kaye DM, Thompson JM, Turner AG, Jennings GL, Itsiopoulos C & Esler MD (1995). Regional sympathetic nervous activation after a large meal in humans. Clin Sci (Lond) 89, 145-154.
26. Dampney RA (2011). Arcuate nucleus - a gateway for insulin's action on sympathetic activity. J Physiol 589, 2109-2110.
27. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J & Felber JP (1981). The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30, 1000-1007.
28. Dengo AL, Dennis EA, Orr JS, Marinik EL, Ehrlich E, Davy BM & Davy KP (2010). Arterial destiffening with weight loss in overweight and obese middle-aged and older adults. Hypertension 55, 855-861.
29. Dixon JB (2009). The effect of obesity on health outcomes. Mol Cell Endocrinol 316, 104-108.
30. Dulloo AG (2002). Biomedicine. A sympathetic defense against obesity. Science 297, 780-781.
31. Dulloo AG & Jacquet J (2001). An adipose-specific control of thermogenesis in body weight regulation. Int J Obes Relat Metab Disord 25(Suppl 5), S22-29.
32. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G & Lambert E (2006). Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48, 787-796.
33. Esler M, Vaz M, Collier G, Nestel P, Jennings G, Kaye D, Seals D & Lambert G (1998). Leptin in human plasma is derived in part from the brain, and cleared by the kidneys. Lancet 351, 879.
34. Fagius J & Berne C (1994). Increase in muscle nerve sympathetic activity in humans after food intake. Clin Sci (Lond) 86, 159-167.
35. Febbraio MA & Pedersen BK (2005). Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 33, 114-119.
36. Feingold KR, Doerrler W, Dinarello CA, Fiers W & Grunfeld C (1992). Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 130, 10-16.
37. Festa A, D'Agostino R, Tracy RP & Haffner SM (2002). Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51, 1131-1137.
38. Finkelstein EA, Trogdon JG, Cohen JW & Dietz W (2009). Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff 28, w822-831.
39. Florian JP & Pawelczyk JA (2009). Non-esterified fatty acids increase arterial pressure via central sympathetic activation in humans. Clin Sci 118, 61-69.
40. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ & Sattar N (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51, 1596-1600.
41. Friedman JM (2000). Obesity in the new millennium. Nature 404, 632-634.
42. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE & Lodish HF (2001). Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98, 2005-2010.
43. Gadegbeku CA, Dhandayuthapani A, Sadler ZE, Egan BM (2002). Raising lipids acutely reduces baroreflex sensitivity. Am J Hypertens 15(6), 479-485.
44. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG & Zucker IH (2005). Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 112, 1763-1770.
45. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P & Baron AD (1998). Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 101, 2377-2386.
46. Gorzelniak K, Engeli S, Janke J, Luft FC & Sharma AM (2002). Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 20, 965-973.
47. Grassi G, Colombo M, Seravalle G, Spaziani D & Mancia G (1998a). Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 31, 64-67.
48. Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB & Mancia G (2004). Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 22, 2363-2369.
49. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL & Mancia G (2005). Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48, 1359-1365.
50. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F & Mancia G (1995). Sympathetic activation in obese normotensive subjects. Hypertension 25, 560-563.
51. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F & Mancia G (1998b). Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 97, 2037-2042.
52. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, Facchini A & Mancia G (2003). CROSS Study. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 9, 1761-1769.
53. Grassi G, Seravalle G, Dell'Oro Turri C, Bolla GB & Mancia G (2000). Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 36, 538-542.
54. Grekin RJ, Ngarmukos CO, Williams DM, Supiano MA (2005). Renal norepinephrine spillover during infusion of nonesterified fatty acids. Am J Hypertens 18(3), 422-426.
55. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF & Shulman GI (1999). Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48, 1270-1274.
56. Grill HJ (2006). Distributed neural control of energy balance: contributions from hindbrain and hypothalamus. Obesity 14, 216S-221S.
57. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD & Gold PW (2000). Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A 97, 6079-6084.
58. Han C, Liu J, Liu X & Li M (2010). Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells. Atherosclerosis 212, 206-212.
59. Han Y, Zhang Y, Wang HJ, Gao XY, Wang W & Zhu GQ (2005). Reactive oxygen species in paraventricular nucleus modulates cardiac sympathetic afferent reflex in rats. Brain Res 1058, 82-90.
60. Hausberg M, Mark AL, Hoffman RP, Sinkey CA & Anderson EA (1995). Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens 13, 1015-1021.
61. Haynes WG, Morgan DA, Walsh SA, Mark AL & Sivitz WI (1997a). Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 100, 270-278.
62. Haynes WG, Sivitz WI, Morgan DA, Walsh SA & Mark AL (1997b). Sympathetic and cardiorenal actions of leptin. Hypertension 30, 619-623.
63. Hedeskov CJ (1980). Mechanism of glucose-induced insulin secretion. Physiol Rev 60, 442-509.
64. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS & Spiegelman BM (1994). Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134, 264-270.
65. Hopkins DF & Williams G (1997). Insulin receptors are widely distributed in human brain and bind human and porcine insulin with equal affinity. Diabet Med 14, 1044-1050.
66. Hotamisligil GS, Arner P, Caro JF, Atkinson RL & Spiegelman BM (1995). Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95, 2409-2415.
67. Hotamisligil GS, Budavari A, Murray D & Spiegelman BM (1994). Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J Clin Invest 94, 1543-1549.
68. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T & Matsuzawa Y (2000). Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20, 1595-1599.
69. Huber DA & Schreihofer AM (2010). Attenuated baroreflex control of sympathetic nerve activity in obese Zucker rats by central mechanisms. J Physiol 588, 1515-1525.
70. Huggett RJ, Burns J, Mackintosh AF & Mary DA (2004). Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 44, 847-852.
71. 2+ in high-fat-fed rats. Metabolism 51, 912-918.
72. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K & Nagai R (2004). Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine endothelial cell interactions. Biochem Biophys Res Commun 314, 415-419.
73. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA & Benjamin EJ (2003). Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23, 434-439.
74. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK & Ruderman NB (2004). AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320, 449-454.
75. Kern PA, Ranganathan S, Li C, Wood L & Ranganathan G (2001). Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280, E745-751.
76. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R & Simsolo RB (1995). The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95, 2111-2119.
77. Kohler HP & Grant PJ (2000). Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342, 1792-1801.
78. Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G & Olefsky JM (2002). Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab 87, 226-234.
79. Kumar S, Olukoga AO, Gordon C, Mawer EB, France M, Hosker JP, Davies M & Boulton AJ (1994). Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin Endocrinol (Oxf) 40, 47-53.
80. Lakka TA, Lakka HM, Salonen R, Kaplan GA & Salonen JT (2001). Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Arteriosclerosis 154, 497-504.
81. Lam TK, Schwartz GJ & Rossetti L (2005). Hypothalamic sensing of fatty acids. Nat Neurosci 8, 579-584.
82. Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, Chopra R, Wong C, Chatzivlastou K, Head G, Straznicky N, Esler M, Schlaich M & Lambert G (2010). Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension 56, 351-358.
83. Lambert E, Straznicky N, Schlaich M, Esler M, Dawood T, Hotchkin E & Lambert G (2007). Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 50, 862-868.
84. Landsberg L (1990). Insulin resistance, energy balance and sympathetic nervous system activity. Clin Exp Hypertens A 12, 817-830.
85. Landsberg L & Young JB (1981). Diet-induced changes in sympathoadrenal activity: implications for thermogenesis. Life Sci 28, 1801-1819.
86. Landsberg L & Young JB (1993). Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic thermogenic drugs. Int J Obes Relat Metab Disord 17(Suppl 1), S29-34.
87. Lang CH & Dobrescu C (1989). Sepsis-induced changes in in vivo insulin action in diabetic rats. Am J Physiol Endocrinol Metab 3, E301-308.
88. Lau DCW, Dhillon G, Yan H, Szmitko PE & Verma S (2005). Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288, H2031-H2041.
89. Lee ZS, Critchley JA, Tomlinson B, Young RP, Thomas GN, Cockram CS, Chan TY & Chan JC (2001). Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism 50, 135-143.
90. Lembo G, Napoli R, Capaldo B, Rendina V, Laccarino G, Volpe M, Trimarco B & Saccà L (1992). Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest 90, 24-29.
91. Lenczowski MJ, Bluthé RM, Roth J, Rees GS, Rushforth DA, van Dam AM, Tilders FJ, Dantzer R, Rothwell NJ & Luheshi GN (1999). Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats. Am J Physiol Regul Integr Comp Physiol 276, R652-658.
92. Lind L, Siegbahn A, Ingelsson E, Sundstrom J & Arnlov J (2011). A detailed cardiovascular characterization of obesity without the metabolic syndrome. Arterioscler Thromb Vasc Biol 31, e27-34.
93. Lucini D, Cusumano G, Bellia A, Kozakova M, Difede G, Lauro R & Pagani M (2006). Is reduced baroreflex gain a component of the metabolic syndrome? Insights from the LINOSA study. J Hypertens 24, 361-370.
94. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y & Matsubara K (1996). cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun 221, 286-289.
95. Mark AL, Agassandian K, Morgan DA, Liu X, Cassell MD & Rahmouni K (2009). Leptin signaling in the nucleus tractus solitarii increases sympathetic nerve activity to the kidney. Hypertension 53, 375-380.
96. Mark AL, Correia M, Morgan DA, Shaffer RA & Haynes WG (1999). State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 33, 537-541.
97. Mastorakos G, Weber JS, Magiakou MA, Gunn H & Chrousos GP (1994). Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 79, 934-939.
98. 2-Adrenoceptor polymorphisms relate to insulin resistance and sympathetic overactivity as early markers of metabolic disease in nonobese, normotensive individuals. Am J Hypertens 18, 1009-1014.
99. Matsubara M, Maruoka S & Katayose S (2002). Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147, 173-180.
100. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H & Ishii M (1991). Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol Regul Integr Comp Physiol 261, R690-696.
101. McCarty MF (2004). Elevated sympathetic activity may promote insulin resistance syndrome by activating alpha-1 adrenergic receptors on adipocytes. Med Hypotheses 62, 830-838.
102. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE, York DA & Pinkney J (2001). beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 86, 5864-5869.
103. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S & Coppack SW (1997). Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 82, 4196-4200.
104. Monahan KD, Dyckman DJ & Ray CA (2007). Effect of acute hyperlipidemia on autonomic and cardiovascular control in humans. J Appl Physiol 103, 162-169.
105. Monahan KD, Eskurza I & Seals DR (2004). Ascorbic acid increases cardiovagal baroreflex sensitivity in healthy older men. Am J Physiol Heart Circ Physiol 286, H2113-2117.
106. Monroe MB, Van Pelt RE, Schiller BC, Seals DR & Jones PP (2000). Relation of leptin and insulin to adiposity associated elevations in sympathetic activity with age in humans. Int J Obes Relat Metab Disord 24, 1183-1187.
107. Morgan DA, Balon TW, Ginsberg BH & Mark AL (1993). Nonuniform regional sympathetic nerve responses to hyperinsulinemia in rats. Am J Physiol Regul Integr Comp Physiol 264, R423-427.
108. Munhoz RT, Negrão CE, Barretto AC, Ochiai ME, Cardoso JN, Morgado PC, Del Carlo CH & Ramires JA (2009). Microneurography and venous occlusion plethysmography in heart failure: correlation with prognosis. Arq Bras Cardiol 92, 46-53.
109. Muntzel MS, Morgan DA, Mark AL & Johnson AK (1994). Intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity. Am J Physiol Regul Integr Comp Physiol 267, R1350-1355.
110. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Choe I, Winnicki M, Palatini P, Sivitz WI & Somers VK (2001). Leptin interacts with heart rate but not sympathetic nerve traffic in healthy male subjects. J Hypertens 19, 1089-1094.
111. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T & Matsuzawa Y (2002). Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51, 2734-2741.
112. O'Hare JA, Minaker KL, Meneilly GS, Rowe JW, Pallotta JA & Young JB (1989). Effect of insulin on plasma norepinephrine and 3, 4-dihydroxyphenylalanine in obese men. Metabolism 38, 322-329.
113. Orr JS, Gentile CL, Davy BM & Davy KP (2008). Large artery stiffening with weight gain in humans: role of visceral fat accumulation. Hypertension 51, 1519-1524.
114. Perseghin G, Ghosh S, Gerow K & Shulman GI (1997). Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46, 1001-1009.
115. Petersen AM & Pedersen BK (2005). The anti-inflammatory effect of exercise. J Appl Physiol 98, 1154-1162.
116. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA & Pedersen BK (2005). Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288, E155-162.
117. Rahmouni K, Morgan DA, Morgan GM, Liu X, Sigmund CD, Mark AL & Haynes WG (2004). Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest 114, 652-658.
118. Reusch JE, Begum N, Sussman KE & Draznin B (1991). Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology 129, 3269-3273.
119. Ridker PM, Buring JE, Cook NR & Rifai N (2003). C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107, 391-397.
120. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J & Landsberg L (1981). Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30, 219-225.
121. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, Wiesner GH, Brunner-La Rocca HP & Esler MD (1999). Neural mechanisms in human obesity-related hypertension. J Hypertens 17, 1125-1133.
122. Russell CD, Petersen RN, Rao SP, Ricci MR, Prasad A, Zhang Y, Brolin RE & Fried SK (1998). Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am J Physiol Endocrinol Metab 275, E507-E515.
123. Sander D, Winbeck K, Klingelhöfer J, Etgen T & Conrad B (2001). Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 57, 833-838.
124. Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, Lambert E, Chopra R, Socratous F, Hennebry S, Eikelis N, Bohm M, Krum H, Lambert G, Esler MD & Sobotka PA (2011). Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 29, 991-996.
125. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW & Mooney RA (2003). Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278, 13740-13746.
126. Shulman GI (2000). Cellular mechanisms of insulin resistance. J Clin Invest 106, 171-176.
127. Sivenius K, Niskanen L, Laakso M & Uusitupa M (2003). A deletion in the α2B-adrenergic receptor gene and autonomic nervous function in central obesity. Obes Res 11, 962-970.
128. Snitker S, Pratley RE, Nicolson M, Tataranni PA & Ravussin E (1997). Relationship between muscle sympathetic nerve activity and plasma leptin concentration. Obes Res 5, 338-340.
129. Stratakis CA & Chrousos GP (1995). Neuroendocrinology and pathophysiology of the stress system. Ann N Y Acad Sci 771, 1-18.
130. Straznicky NE, Eikelis N, Lambert EA & Esler MD (2008). Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 10, 440-447.
131. Straznicky NE, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, Chopra R, Masuo K, Esler MD, Sari CI, Lambert GW & Lambert EA (2011). The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab 96, E503-508.
132. Straznicky NE, Lambert GW, Masuo K, Dawood T, Eikelis N, Nestel PJ, McGrane MT, Mariani JA, Socratous F, Chopra R, Esler MD, Schlaich MP & Lambert EA (2009a). Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. Am J Clin Nutr 89, 27-36.
133. Straznicky NE, Lambert GW, McGrane MT, Masuo K, Dawood T, Nestel PJ, Eikelis N, Schlaich MP, Esler MD, Socratous F, Chopra R & Lambert EA (2009b). Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. Diabetes 58, 1126-1132.
134. Struck J, Muck P, Trubger D, Handrock R, Weidinger G, Dendorfer A & Dodt C (2002). Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens 20, 1143-1149.
135. Tank J, Jordan J, Diedrich A, Schroeder C, Furlan R, Sharma AM, Luft FC & Brabant G (2003). Bound leptin and sympathetic outflow in nonobese men. J Clin Endocrinol Metab 88, 4955-4959.
136. Thomas GN, Chook P, Qiao M, Huang XS, Leong HC, Celermajer DS & Woo KS (2004). Deleterious impact of "high normal" glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 24, 739-743.
137. Tounian P, Aggoun Y, Dubern B, Varille V, Guy-Grand B, Sidi D, Girardet JP & Bonnet D (2001). Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 358, 1400-1404.
138. Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA & Katsilambros N (1999). Circulating tumor necrosis factor α concentrations are higher in abdominal versus peripheral obesity. Metabolism 48, 1332-1335.
139. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M, Kihara M, Inoue S & Ishii M (1997). Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 6, 629-633.
140. Van De Borne P, Hausberg M, Hoffman RP, Mark AL & Anderson EA (1999). Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Am J Physiol Regul Integr Comp Physiol 276, R178-183.
141. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S & Arner P (2000). Increased adipose angiotensinogen gene expression in human obesity. Obes Res 8, 337-341.
142. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F & Arner P (1998). Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47, 913-917.
143. Vaz M, Jennings G, Turner A, Cox H, Lambert G & Esler M (1997). Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 96, 3423-3429.
144. Vollenweider L, Tappy L, Owlya R, Jéquier E, Nicod P & Scherrer U (1995). Insulin-induced sympathetic activation and vasodilation in skeletal muscle. Effects of insulin resistance in lean subjects. Diabetes 44, 641-645.
145. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P & Scherrer U (1994). Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 93, 2365-2371.
146. Vollenweider P, Tappy L, Randin D, Schneiter P, Jéquier E, Nicod P & Scherrer U (1993). Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 92, 147-154.
147. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C & Jansson JO (2002). Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8, 75-79.
148. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA & Verma S (2003). C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107, 1783-1790.
149. Wernstedt I, Edgley A, Berndtsson A, Fäldt J, Bergström G, Wallenius V & Jansson JO (2006). Reduced stress- and cold-induced increase in energy expenditure in interleukin-6-deficient mice. Am J Physiol Regul Integr Comp Physiol 291, R551-557.
150. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP & Yaffe K (2008). Central obesity and increased risk of dementia more than three decades later. Neurology 71, 1057-1064.
151. Yamauchi T, Oike Y, Kamon J, Waki H, Komeda K, Tsuchida A, Date Y, Li MX, Miki H, Akanuma Y, Nagai R, Kimura S, Saheki T, Nakazato M, Naitoh T, Yamamura K & Kadowaki T (2002). Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 30, 221-226.
152. Young CN, Deo SH, Chaudhary K, Thyfault JP & Fadel PJ (2010). Insulin enhances the gain of arterial baroreflex control of muscle sympathetic nerve activity in humans. J Physiol 588, 3593-3603.
153. Young JB & Landsberg L (1977). Suppression of sympathetic nervous system during fasting. Science 196, 1473-1475.
154. Yudkin JS, Stehouwer CD, Emeis JJ & Coppack SW (1999). C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19, 972-978.
155. Zanzinger J & Czachurski J (2000). Chronic oxidative stress in the RVLM modulates sympathetic control of circulation in pigs. Pflugers Arch 439, 489-494.
156. Zera T, Ufnal M & Szczepanska-Sadowska E (2008). Central TNF-α elevates blood pressure and sensitizes to central pressor action of angiotensin II in the infarcted rats. J Physiol Pharmacol 59, 117-121.
157. Zierath JR, Houseknecht KL, Gnudi L & Kahn BB (1997). High-fat feeding impairs insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect. Diabetes 46, 215-223.
158. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR & Davisson RL (2002). Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 91, 1038-1045.